Assessment of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Plasma Levels in Inflammatory Bowel Diseases

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Gastroenterology

• Publication date

  2004-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1572-0241.2004.30203.xPMID 15447757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombin activatable fibrinolysis inhibitor (TAFI) and the risk of recurrent venous thromboembolism

  2004cited by this paper
• Inflammation and Atherosclerosis

  2004cited by this paper
• Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis

  2004cited by this paper
• Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.

  2004cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

  2003cited by this paper
• Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways

  2003cited by this paper
• Low Vitamin B6 Plasma Levels, a Risk Factor for Thrombosis, in Inflammatory Bowel Disease: Role of Inflammation and Correlation With Acute Phase Reactants

  2003cited by this paper
• C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis

  2003cited by this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography

  2002influential reference
• Inflammation and Atherosclerosis

  2002cited by this paper
• Interleukin 8 and venous thrombosis: evidence 
for a role of inflammation in thrombosis

  2002cited by this paper
• Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.

  2002cited by this paper
• [Celiac disease and Bud-Chiari syndrome: an uncommon association].

  2002cited by this paper
• Pathological haemostasis and "prothrombotic state" in Behçet's disease.

  2002cited by this paper
• Enfermedad celíaca y síndrome de Budd-Chiari: una asociación infrecuente

  2002cited by this paper
• Low Levels of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Chronic Liver Disease

  2001cited by this paper
• Hemostatic imbalance in active and quiescent ulcerative colitis

  2001cited by this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).

  2001cited by this paper
• Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery Disease

  2000influential reference
• No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer.

  2000cited by this paper
• Molecular Cloning and Partial Characterization of Rat Procarboxypeptidase R and Carboxypeptidase N

  2000cited by this paper
• Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.

  2000cited by this paper
• A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998

  2000cited by this paper
• Pro-Carboxypeptidase R is an Acute Phase Protein in the Mouse, Whereas Carboxypeptidase N Is Not1 2

  2000cited by this paper
• Reduced activity of TAFI (thrombin‐activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia

  2000cited by this paper
• Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease.

  1999cited by this paper
• Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease.

  1999cited by this paper
• Markers of Coagulation and Fibrinolysis as Measures of Disease Activity in Inflammatory Bowel Disease

  1998cited by this paper
• Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease.

  1998cited by this paper
• High Prevalence of Hyperhomocysteinemia in Patients with Inflammatory Bowel Disease: a Pathogenic Link with Thromboembolic Complications?

  1998cited by this paper
• Active Site-inactivated Factors VIIa, Xa, and IXa Inhibit Individual Steps in a Cell-based Model of Tissue Factor-initiated Coagulation

  1998cited by this paper
• Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden.

  1997cited by this paper
• Thrombotic vascular risk factors in inflammatory bowel disease.

  1996cited by this paper
• The Significance of Hypofibrinolysis for the Risk of Recurrence of Venous Thromboembolism

  1996cited by this paper
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease

  1995cited by this paper
• Thromboembolism in inflammatory bowel disease: role of platelets.

  1993cited by this paper
• Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.

  1993cited by this paper
• Mucosal capillary thrombi in rectal biopsies

  1992cited by this paper
• Impaired Fibrinolytic Capacity in Patients with Inflammatory Bowel Disease

  1990cited by this paper
• Platelet Count, Platelet Function, Coagulation Activity and Fibrinolysis in the Acute Phase of Inflammatory Bowel Disease

  1990cited by this paper
• Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.

  1989cited by this paper
• Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.

  1989cited by this paper
• Disturbed fibrinolysis in patients with inflammatory bowel disease.

  1989cited by this paper
• Vascular complications of inflammatory bowel disease.

  1986cited by this paper
• Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

  1976cited by this paper
• Noradrenaline in Acute Peripheral Circulatory Failure

  1956cited by this paper
• EXTENSIVE ARTERIAL AND VENOUS THROMBOSIS COMPLICATING CHRONIC ULCERATIVE COLITIS

  1936cited by this paper

• Selective Activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Attenuates Metastatic and Angiogenic Capabilities of Melanoma and Lung Carcinoma in vitro

  2023cites this paper
• The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review

  2022cites this paper
• Venous and arterial thromboembolism in patients with inflammatory bowel diseases

  2021cites this paper
• Coagulation status, fibrinolysis, and platelet dynamics in dogs with chronic inflammatory enteropathy

  2021cites this paper
• A postdischarge venous thromboembolism risk calculator for inflammatory bowel disease surgery.

  2020cites this paper
• Venous Thrombosis in Pediatric Inflammatory Bowel Disease.

  2019cites this paper
• Celiac Disease

  2019cites this paper
• Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

  2018cites this paper
• Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy

  2017cites this paper
• The World of Proteases Across Microbes, Insects, and Medicinal Trees

  2017cites this paper
• Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.

  2016cites this paper
• Section designation: Review article

  2016cites this paper
• Impact of Thrombomodulin and Thrombin-Activatable Fibrinolysis Inhibitor on the Anticoagulant and Profibrinolytic Effects of Rivaroxaban

  2016cites this paper
• Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease: A Prospective Study

  2015influential citation
• The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease

  2015cites this paper
• Thrombosis in inflammatory bowel diseases: what’s the link?

  2015cites this paper
• Massive Pulmonary Embolism Associated with Hemorrhagic Colitis: what is the Link?

  2015cites this paper
• Cardiovascular complications in inflammatory bowel disease.

  2015cites this paper
• The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile

  2015cites this paper
• Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

  2014cites this paper
• Neurological disorders and inflammatory bowel diseases.

  2014cites this paper
• Enteric Syndromes Leading to Malnutrition and Infections

  2014cites this paper
• Neurological disorders and inflammatory bowel diseases

  2014cites this paper
• Celiac Disease and Autoimmune-Associated Conditions

  2013cites this paper
• Venous and arterial disease in inflammatory bowel disease

  2013cites this paper
• Venous Thrombotic Events in Hospitalized Children and Adolescents With Inflammatory Bowel Disease

  2013cites this paper
• Increased Procoagulant Function of Microparticles in Pediatric Inflammatory Bowel Disease: Role in Increased Thrombin Generation

  2013cites this paper
• Involvement of coagulation and hemostasis in inflammatory bowel diseases.

  2012cites this paper
• Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.

  2012cites this paper
• Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

  2012cites this paper
• Celiac Disease: Complications and the role of Infection in Pathogenesis

  2012cites this paper
• Hematological manifestations of celiac disease

  2012cites this paper
• Hematologic manifestations of celiac disease

  2012cites this paper
• Kallikrein – Kinin System and Coagulation System in Inflammatory Bowel Diseases

  2011cites this paper
• Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

  2011cites this paper
• [Hematological disorders in celiac disease].

  2011cites this paper
• Proteases/Antiproteases in Inflammatory Bowel Diseases

  2011cites this paper
• Maladie cœliaque de l’adulte et thromboses : à propos de sept cas. Rôle des facteurs thrombophiliques

  2011cites this paper
• [Adult celiac disease with thrombosis: a case series of seven patients. Role of thrombophilic factors].

  2011cites this paper
• A clinical cardiology perspective of thrombophilias

  2010cites this paper
• Deep Venous Thrombosis After Surgery for Inflammatory Bowel Disease: Is Standard Dose Low Molecular Weight Heparin Prophylaxis Enough?

  2010cites this paper
• Spontaneous right ventricular thrombus in a patient with active ulcerative colitis and protein C deficiency: a review with a case report.

  2010cites this paper
• Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs.

  2010cites this paper
• A case of ulcerative colitis complicated with sequential cerebral and pulmonary thromboembolism

  2009cites this paper
• Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis.

  2009cites this paper
• PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system

  2008cites this paper
• Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease

  2008cites this paper
• Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels

  2008cites this paper
• Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor

  2008cites this paper
• Assessment of Thrombophilic Abnormalities During the Active State of Inflammatory Bowel Disease

  2008cites this paper
• TAFIa inhibitors in the treatment of thrombosis.

  2008cites this paper
• Thrombosis and inflammatory bowel disease-the role of genetic risk factors.

  2008cites this paper
• Quantification of the effects of thrombin activatable fibrinolysis inhibitor and α2-antiplasmin on fibrinolysis in normal human plasma

  2007cites this paper
• Molecular analysis of the human thrombin‐activatable fibrinolysis inhibitor gene promoter

  2007cites this paper
• Risk of thromboembolism in 14 000 individuals with coeliac disease

  2007cites this paper
• Hematologic manifestations of celiac disease.

  2007cites this paper
• Kidney gene expression analysis in a rat model of intrauterine growth restriction reveals massive alterations of coagulation genes.

  2007cites this paper
• Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens

  2007cites this paper
• Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.

  2007cites this paper
• Bioecological control of inflammatory bowel disease.

  2007cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Diseases

  2006cites this paper
• Plasma levels of thrombin activatable fibrinolysis inhibitor antigen in active and inactive inflammatory bowel disease.

  2006influential citation
• Antibodies to tissue‐type plasminogen activator (t‐PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t‐PA and possible implications in thrombosis

  2006cites this paper
• Systemic Thromboembolism in Inflammatory Bowel Disease: Mechanisms and Clinical Applications

  2005cites this paper
• Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice1

  2005cites this paper
• Therapy Insight: vascular complications in patients with inflammatory bowel disease

  2005cites this paper
• Development of ELISAs Measuring the Extent of TAFI Activation

  2005cites this paper
• Thromboembolism—an Important Manifestation of Inflammatory Bowel Disease

  2004cites this paper
• Exploring the relationships between inflammatory response and coagulation cascade in inflammatory bowel disease.

  2004cites this paper
• The Occurrence of Thrombosis in In fl ammatory Bowel Disease Is Re fl ected in the Clot Lysis Pro fi le

  year unknowncites this paper